...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: As Pfizer charges ahead....

Yes, in May they issued 10% convertible debentures for $6 million that involved the patents, other IP and assets to an HL subsidiary. This was for only one year so will come up quickly. They have nothing else to offer in any loan type financing. HL could convert these in a steal of a deal with where the share price has gone. As with the CITI loan, RVX has to come up with some kind of financing to pay the debentures off before they lose the IP or hope HL chooses to convert.

With managements failure, the company is always on the edge of losing everything. They are not to be lauded for escaping this, it is failure and that is what shows in the share price regardless of the science.

Share
New Message
Please login to post a reply